Siemens Healthineers has released a hemoglobin A1c (HbA1c) test that it believes will help clinicians diagnose and monitor patients with diabetes evaluated with its Atellica CH diagnostic unit.
The Atellica CH enzymatic hemoglobin A1c assay offers accurate results that may be used for the management of patients with diabetes, Siemens said in a May 14 statement. The HbA1c rollout is part of a broader company effort in laboratory and point-of-care systems aimed at harmonizing tests.
